Pfizer Must Pay Kaiser Cost-Difference Of Cheaper Drugs Under Neurontin Marketing Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Judge Patti Saris finds Pfizer fraudulently marketed its anti-epileptic in violation of California law and orders the company to pay Kaiser $95 million.
You may also be interested in...
Pharma Strikes Out At Supreme Court As Three Recent Cert Petitions Fail
Pfizer, Cephalon and former InterMune CEO Scott Harkonen will find no relief from the high court.
Who's Running Pfizer's Neurontin Antitrust Defense? Judge Says Company, Counsel "Inverted" Their Roles
A magistrate judge says Pfizer has failed to find a witness who knows the basis for the company's denial of off-label marketing of the anti-epileptic; direct purchasers granted class certification.
Who's Running Pfizer's Neurontin Antitrust Defense? Judge Says Company, Counsel "Inverted" Their Roles
A magistrate judge says Pfizer has failed to find a witness who knows the basis for the company's denial of off-label marketing of the anti-epileptic; direct purchasers granted class certification.